Work

Muscle weakness, myositis and scleroderma induced by durvalumab

Year: 2024

Type: article

Abstract: Immune checkpoint inhibitors (ICI) have shown a change in the prognosis of multiple malignancies, but a wide range of immune-related adverse events (irAE) can occur. We present a case of a 72-year-old Caucasian male treated with Durvalumab for epidermic lung cancer, who developed a sclerosis-like syndrome and myositis. The patient was admitted to our hospital with respiratory failure due to muscular weakness and pulmonary hypertension. Differential diagnoses pointed to scleroderma secondary to ICI. We report a rare case of ICI-induced axonal polyneuropathy, myopathy and RNA polymerase III positive scleroderma. As this therapy is widely recommended, adverse effects may become more frequent. Early identification and treatment are warranted.

Source: Respirology Case Reports

DOI: 10.1002/rcr2.70084

Authors: Josu Aguado Suquia, Pilar Carballosa de Miguel, Alba Naya Prieto, Maria Jesus Lobo Rebollo, Teresa Blázquez Sánchez, Sarah Béatrice Heili Frades

Institutions: Hospital Universitario de Burgos, Hospital Universitario Fundación Jiménez Díaz

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,130